新诊断的胶质母细胞瘤的肿瘤治疗野（TTFields）治疗与总生存率的关系。

IF 2.8 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-07-01 Epub Date: 2025-02-01 DOI:10.1007/s12094-025-03849-6

Siddharth Shah, Aiswarya Nag, Brandon Lucke-Wold

{"title":"新诊断的胶质母细胞瘤的肿瘤治疗野（TTFields）治疗与总生存率的关系。","authors":"Siddharth Shah, Aiswarya Nag, Brandon Lucke-Wold","doi":"10.1007/s12094-025-03849-6","DOIUrl":null,"url":null,"abstract":"Glioblastoma (GBM) is a rare and aggressive primary central nervous system tumor with high morbidity and mortality. Standard treatments include surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy, but these options are often insufficient and cause severe side effects. Tumor Treating Fields (TTFields) have emerged as a fourth treatment, offering improved survival, better prognosis, and minimal side effects, significantly enhancing the quality of life for GBM patients. For newly diagnosed cases, TTFields combined with TMZ is the recommended standard of care for eligible patients. Current GBM therapy focuses on extending survival while reducing harm. Ongoing research seeks to explore TTFields in innovative radiological-based therapeutic paradigms.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"2904-2912"},"PeriodicalIF":2.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of tumor treating fields (TTFields) therapy with overall survival in newly diagnosed glioblastoma.\",\"authors\":\"Siddharth Shah, Aiswarya Nag, Brandon Lucke-Wold\",\"doi\":\"10.1007/s12094-025-03849-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glioblastoma (GBM) is a rare and aggressive primary central nervous system tumor with high morbidity and mortality. Standard treatments include surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy, but these options are often insufficient and cause severe side effects. Tumor Treating Fields (TTFields) have emerged as a fourth treatment, offering improved survival, better prognosis, and minimal side effects, significantly enhancing the quality of life for GBM patients. For newly diagnosed cases, TTFields combined with TMZ is the recommended standard of care for eligible patients. Current GBM therapy focuses on extending survival while reducing harm. Ongoing research seeks to explore TTFields in innovative radiological-based therapeutic paradigms.\",\"PeriodicalId\":50685,\"journal\":{\"name\":\"Clinical & Translational Oncology\",\"volume\":\" \",\"pages\":\"2904-2912\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-025-03849-6\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03849-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

胶质母细胞瘤（GBM）是一种罕见的侵袭性原发性中枢神经系统肿瘤，发病率和死亡率高。标准治疗包括手术、放疗（RT）和替莫唑胺（TMZ）化疗，但这些选择往往不够充分，并导致严重的副作用。肿瘤治疗场（TTFields）已成为第四种治疗方法，可提高生存期，改善预后，副作用最小，显著提高GBM患者的生活质量。对于新诊断的病例，TTFields联合TMZ是推荐给符合条件的患者的护理标准。目前GBM治疗的重点是延长生存期，同时减少危害。正在进行的研究旨在探索创新放射治疗范例中的TTFields。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Association of tumor treating fields (TTFields) therapy with overall survival in newly diagnosed glioblastoma.

Glioblastoma (GBM) is a rare and aggressive primary central nervous system tumor with high morbidity and mortality. Standard treatments include surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy, but these options are often insufficient and cause severe side effects. Tumor Treating Fields (TTFields) have emerged as a fourth treatment, offering improved survival, better prognosis, and minimal side effects, significantly enhancing the quality of life for GBM patients. For newly diagnosed cases, TTFields combined with TMZ is the recommended standard of care for eligible patients. Current GBM therapy focuses on extending survival while reducing harm. Ongoing research seeks to explore TTFields in innovative radiological-based therapeutic paradigms.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.